| Execution period | 18 months |
|---|
NSE filing, NSE: BALPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Bal Pharma Ltd: key numbers
- Share price
- ₹86.17
- Market cap
- ₹137.2 Cr
- Revenue (annual)
- ₹311.7 Cr
- Net profit (annual)
- ₹6.28 Cr
- P/E (TTM)
- 19.0×Sector 46.1×
- Promoter holding
- 50.86%+0.00% QoQ
- FII holding
- 0.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bal Pharma Ltd
All →Bal Pharma Other Announcement
Bal Pharma Ltd has filed its quarterly shareholding pattern as mandated under Regulation 31(1)(b) of the SEBI Listing Regulations.
Bal Pharma Dividend
Bal Pharma disbursed its FY25-26 final dividend of ₹1.20 per share on October 9, 2026. Dividends for shareholders with incomplete KYC or bank details have been withheld.
Bal Pharma Management Change
Bal Pharma Limited announced a change in designations for directors Ravindra Kumar Kothari and Virupakshaya Himesh, effective October 1, 2026.
Bal Pharma Annual General Meeting
Bal Pharma Ltd held its 39th Annual General Meeting on September 24, 2026, where shareholders transacted all business items as per the notice.
Bal Pharma Price Movement Clarification
Bal Pharma has clarified that the recent significant movement in its share price is purely market-driven and not due to any undisclosed price-sensitive information.
Bal Pharma Other Announcement
Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ended March 31, 2026, in compliance with SEBI regulations.
Other capital structure change announcements
All →Emkay Global Financial Services Capital Structure Change
Emkay Global will invest ₹30.00 Crore in cash in wholly owned subsidiary Emkay Capital. The related-party deal completes within 90 days.
- Value
- ₹30.00 Cr
- Execution
- Within 90 days
OnEMI Technology Solutions Capital Structure Change
OnEMI will invest ₹624.15 Crore in its wholly owned subsidiary Si Creva via rights subscription. Funds come from preferential issue proceeds, completing by December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
Meesho Capital Structure Change
Meesho approved up to Rs.400 Crore capital infusion into its wholly owned subsidiary, Meesho Payments. Board also approved a new subsidiary and further Kirana Club investments.
- Value
- ₹400.0 Cr
Womancart Capital Structure Change
Womancart Limited submitted its draft letter of offer for a rights issue of up to Rs.1,200 lakhs to eligible shareholders. The issue is pending in-principle approval from NSE Emerge, with the price, ratio and dates still blank.
- Value
- ₹12.00 Cr
Hero MotoCorp Capital Structure Change
Hero MotoCorp's board approved up to ₹300 Crore additional investment in wholly-owned subsidiary HMCL Netherlands B.V., in tranches over two years. Quarterly results were also approved.
- Value
- ₹300.0 Cr
- Execution
- 2 years, in one or more tranches
Great Eastern Shipping Company Capital Structure Change
Great Eastern Shipping bought back 88,877 equity shares on 28 October 2026 at an average of Rs.1,529.71. Total shares bought back under the open-market buyback now stand at 38,48,494.
- Value
- ₹13.60 Cr